The HIV-1 accessory protein Vpu enhances viral infectivity by modulating several host cell proteins that are detrimental to the virus, including CD4 and BST-2 (tetherin), and preventing them from being incorporated into viral particles. Importantly, Vpu activities result in the protection of HIV-1 infected cells from cellular immune responses such as antibody dependent cell-mediated cytotoxicity (ADCC). For this reason, inhibitors of Vpu activity could be used to enhance immune killing of HIV infected cells in patients. This type of inhibitor could be an important component of therapies aimed at eliminating reservoirs of HIV infected cells. The Johnson lab serendipitously discovered that Vpu targets the viral glycoprotein from Gibbon ape Leukemia Virus (GaLV Env) and prevents it from being incorporated into HIV-1 viral particles. Therefore, inhibiting Vpu activity greatly enhances infectivity when HIV-1 is used with this glycoprotein. GaLV Env was selected as a surrogate Vpu target in an assay for identifying inhibitors of Vpu activity. Unlike other types of Vpu assays, the output (infectivity) is quantitative in nature and very amenable to a high throughput screening. Along with collaborators at Southern Research Institute (SRI, see letter of support), a large high throughput screening (HTS) campaign of over 650,000 compounds was initiated using this assay in hopes of finding appropriate Vpu inhibitors that could be advanced to clinical applications. This screen and dose response validation of the hits was completed in August 2017 and identified 205 candidate Vpu-inhibiting compounds. The ultimate goal of this project is develop compounds that can be used to block Vpu activity in a clinical setting. The objective of this proposal is to determine which compounds from the HTS campaign are most suitable for further development as clinical Vpu inhibitors. 1. Conduct hit-to-lead studies to identify the best compound candidates. a. Screen for compounds that do not block cellular SCF Ubiquitin machinery (off target). b. Screen for compounds with Vpu-specific activity. c. Screen with advanced toxicity and ADME assays to identify most desirable compounds. 2. Select for compounds with the desired biological activity. a. Screen for compounds that block Vpu antagonism of CD4. b. Screen for compounds that block Vpu antagonism of BST-2. c. Screen for compounds that directly bind to Vpu.

Public Health Relevance

Thanks to the advances of HIV therapy, the number of people dying from HIV continues to drop, but the number of people living with HIV-1 continues to increase (36.7 million in 2015 according to the World Health Organization). In hopes of developing therapies that attempt to eliminate HIV reservoirs in infected patients, this project aims to characterize novel compounds that inhibit a viral protein (Vpu) that helps these viral reservoirs escape immune detection. Such compounds could be utilized to enhance immunotherapy strategies and possibly eliminate viral reservoirs in patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI136611-02
Application #
9645599
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Miller, Roger H
Project Start
2018-02-09
Project End
2020-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Missouri-Columbia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
153890272
City
Columbia
State
MO
Country
United States
Zip Code
65211
Song, Yul Eum; Cyburt, Daniel; Lucas, Tiffany M et al. (2018) ?TrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin. Viruses 10: